Article Text

Download PDFPDF
Evidence for effectiveness of a national HPV vaccination programme: national prescription data from New Zealand
  1. Nick Wilson1,
  2. Jane Morgan2,
  3. Michael G Baker1
  1. 1University of Otago, Wellington, New Zealand
  2. 2Sexual Health Service, Waikato District Health Board, Hamilton, New Zealand
  1. Correspondence to Dr Nick Wilson, University of Otago, Wellington, PO Box 7343, Wellington 6021, New Zealand; nick.wilson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To prevent cervical cancer, a government-funded vaccination programme against human papillomavirus (HPV) infection started in New Zealand in 2008. After an initial catch-up phase, vaccination with a quadrivalent vaccine was routinely offered from year 2011 onwards to girls in school year 8 (typically age 12 years) or in primary care settings at age 12.

To better understand the impact of this vaccination programme, we examined national prescription data from the government's pharmaceutical purchasing agency (PHARMAC). From this agency, we obtained national data for both imiquimod cream (ie, Aldara) and for podophyllum resin-based products …

View Full Text


  • Contributors NW and JM independently initiated the project and then worked together. JM obtained the data, which were analysed by NW. All authors contributed to the preparation of the manuscript.

  • Funding Health Research Council of New Zealand.

  • Competing interests None.

  • Ethics approval The study was exempt from ethical review as it involved the use of existing collections of secondary non-identifiable data.

  • Provenance and peer review Not commissioned; internally peer reviewed.